Xact Kapitalforvaltning AB increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,443 shares of the biopharmaceutical company’s stock after acquiring an additional 1,122 shares during the period. Xact Kapitalforvaltning AB’s holdings in Alnylam Pharmaceuticals were worth $1,839,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its holdings in Alnylam Pharmaceuticals by 5.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 277,352 shares of the biopharmaceutical company’s stock worth $33,033,000 after acquiring an additional 14,936 shares during the period. Franklin Resources Inc. increased its holdings in Alnylam Pharmaceuticals by 155.6% during the 4th quarter. Franklin Resources Inc. now owns 50,400 shares of the biopharmaceutical company’s stock worth $6,403,000 after acquiring an additional 30,680 shares during the period. Teachers Advisors LLC increased its holdings in Alnylam Pharmaceuticals by 8.3% during the 4th quarter. Teachers Advisors LLC now owns 102,781 shares of the biopharmaceutical company’s stock worth $13,058,000 after acquiring an additional 7,911 shares during the period. Schroder Investment Management Group bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $409,000. Finally, Green Valley Investors LLC bought a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $17,281,000. 90.21% of the stock is currently owned by institutional investors and hedge funds.
In other news, SVP Laurie Keating sold 1,563 shares of the company’s stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $105.04, for a total value of $164,177.52. Following the completion of the sale, the senior vice president now owns 16,063 shares of the company’s stock, valued at approximately $1,687,257.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.70% of the stock is currently owned by corporate insiders.
A number of analysts recently weighed in on the stock. ValuEngine lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 21st. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 17th. Jefferies Financial Group reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 2nd. Evercore ISI began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 28th. They issued a “line” rating and a $143.00 price target for the company. Finally, B. Riley reissued a “buy” rating and issued a $200.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, April 2nd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $140.38.
Shares of Alnylam Pharmaceuticals opened at $98.51 on Wednesday, Marketbeat Ratings reports. Alnylam Pharmaceuticals, Inc. has a 52-week low of $70.76 and a 52-week high of $153.99. The firm has a market capitalization of $10.06 billion, a PE ratio of -18.18 and a beta of 2.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.61 and a quick ratio of 14.61.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.47) by $0.06. Alnylam Pharmaceuticals had a negative net margin of 565.20% and a negative return on equity of 36.81%. The company had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. During the same quarter in the prior year, the company earned ($1.25) EPS. The firm’s revenue was up 15.3% on a year-over-year basis. equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.7 EPS for the current year.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.